Should I buy or sell LumiraDx stock right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last twelve months. There are currently...
What is LumiraDx's stock price forecast for 2022?
3 analysts have issued 1 year price targets for LumiraDx's shares. Their forecasts range from $8.00 to $20.00. On average, they predict LumiraDx's...
How has LumiraDx's stock price performed in 2022?
LumiraDx's stock was trading at $8.91 on January 1st, 2022. Since then, LMDX shares have decreased by 58.0% and is now trading at $3.74. View the...
When is LumiraDx's next earnings date?
LumiraDx is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for LumiraDx .
Who are LumiraDx's key executives?
LumiraDx's management team includes the following people: Mr. Ron Zwanziger , CEO, Co-Founder & Chairman (Age 68) Dr. David Scott Ph.D. , CTO,...
Who are some of LumiraDx's key competitors?
Some companies that are related to LumiraDx include Organogenesis (ORGO) , Theravance Biopharma (TBPH) , Erasca (ERAS) , CTI BioPharma (CTIC) ,...
What is LumiraDx's stock symbol?
LumiraDx trades on the NASDAQ under the ticker symbol "LMDX."
Who are LumiraDx's major shareholders?
LumiraDx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Account Management LLC (0.55%).
Which major investors are selling LumiraDx stock?
LMDX stock was sold by a variety of institutional investors in the last quarter, including Account Management LLC.
About LMDX
Analyst Forecast
LumiraDx is a next-generation point of care, or POC, diagnostic company. We have developed and launched our LumiraDx Platform, or Platform, which is an integrated system comprised of a small, versatile POC instrument, or Instrument, precise, low-cost microfluidic test strips, and seamless, secure digital connectivity.
News
According to 4 analysts, the average rating for LumiraDx stock is "Strong Buy." The 12-month stock price forecast is 15.06, which is an increase of 100.53% from the latest price.
About LumiraDx
The mean of analysts' price targets for LumiraDx Limited (LMDX) points to a 53.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...
Headlines
LumiraDx Limited is a point of care diagnostics company. Its testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and workplaces to screen, diagnose, and monitor wellness as well as disease.
